1. Home
  2. ABEO

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Founded: N/A Country:
United States
United States
Employees: N/A City: CLEVELAND
Market Cap: 87.3M IPO Year: 1980
Target Price: $20.50 AVG Volume (30 days): 720.0K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.20 EPS Growth: N/A
52 Week Low/High: $2.83 - $9.01 Next Earning Date: 05-15-2024
Revenue: $3,500,000 Revenue Growth: 227.72%
Revenue Growth (this year): 420.2% Revenue Growth (next year): 298.32%

ABEO Daily Stock ML Predictions

Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Alland Leila ABEO Director May 16 '24 Buy $4.71 11,000 $51,799.00 82,857 SEC Form 4
Charles Faith L. ABEO Director Apr 26 '24 Buy $3.28 7,550 $24,764.00 78,323 SEC Form 4
O'Malley Brendan M. ABEO SVP, General Counsel Apr 25 '24 Buy $3.24 8,600 $27,864.00 188,718 SEC Form 4
Vazzano Joseph Walter ABEO Chief Financial Officer Apr 25 '24 Buy $3.14 5,608 $17,609.12 233,868 SEC Form 4
Seshadri Vishwas ABEO Chief Executive Officer Feb 6 '24 Buy $4.39 20,000 $87,800.00 528,260 SEC Form 4
Alvino Mark ABEO Director Jan 17 '24 Sell $5.11 7,084 $36,199.24 62,816 SEC Form 4

Share on Social Networks: